Table 2.
Aging and GLP-1 on left ventricular and systemic hemodynamics after 3 weeks of GLP-1 treatment and before the onset of DCM
| Young | Old | ||||
|---|---|---|---|---|---|
| Control | Old-Control | Old + GLP-1 | |||
| n = 8 | n = 9 | p value* | n = 7 | p value* | |
| LVESP ( mmHg) | 118 ± 4 | 132 ± 10 | NS | 130 ± 10 | NS |
| LVEDP (mmHg) | 9 ± 1 | 11 ± 2 | NS | 10 ± 3 | NS |
| LV dP/dt ( mmHg /sec) | 2881 ± 121 | 2801 ± 176 | NS | 2912 ± 200 | NS |
| LV tau (msec) | 18 ± 1 | 25 ± 2 | <0.01 | 19 ± 1† | NS |
| MAP ( mmHg) | 89 ± 3 | 107 ± 7 | <0.05 | 102 ± 5 | <0.05 |
| Heart Rate (min-1 ) | 90 ± 4 | 101 ± 10 | NS | 99 ± 12 | NS |
| CO (L/min) | 2.7 ± 0.3 | 2.5 ± 0.3 | NS | 2.5 ± 0.4 | NS |
| LVEF (%) | 54 ± 4 | 50 ± 5 | NS | 51 ± 4 | NS |
| SVR (dyne-sec-cm-5) | 2649 ± 267 | 3421 ± 224 | <0.05 | 3164 ± 123 | NS |
| MVO2 (ml O2/min) | 150 ± 21 | 313 ± 39 | <0.01 | 243 ± 22† | <0.01 |
| Coronary Flow (ml/min) | 25 ± 3 | 26 ± 4 | NS | 27 ± 4 | NS |
| LVEDD (mm) | 40 ± 3 | 40 ± 3 | NS | 41 ± 3 | NS |
| LVESD (mm) | 33 ± 2 | 34 ± 3 | NS | 33 ± 3 | NS |
Data is presented as Mean ± SEM; *Compared to young; † p < 0.05 compared to Old-Control; Old-Control, old dogs placebo; Old + GLP-1, old dogs GLP-1 treated; LVESP, left ventricle end-systolic pressure; LVEDP, left ventricle end-diastolic pressure; LV dP/dt, left ventricle rate of rise of left ventricular pressure; tau, isovolumic relaxation time constants; MAP, mean arterial pressure; CO, cardiac output; LVEF, left ventricle ejection fraction; SVR, systemic vascular resistance; MVO2, myocardial oxygen consumption, LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameters.